Source: Tongxiyi
Crowne Plaza Wenjiang Chengdu
Antibody-Drug Conjugates（ADC）The development is booming due to its remarkable efficacy and enormous potential in pan-cancer and low-expression treatment fields. Multinational corporations (MNCs) are eager to deeply invest in this area, leading to a wave of "ADC going global" in China. Among them, located in Chengdu Medical City,Kelun-BiotechThe huge deals between Biokin, Merck, and BMS were particularly eye-catching.
Over the past two years, radiopharmaceuticals（RDC）It is also becoming a hot spot. Bioconjugation technology is becoming the largest engine for innovation in the global pharmaceutical industry.Jointly Create the Future of the Bioconjugate Drug Industry! On April 18th-19th, more than a hundred experts from leading bioconjugate drug development companies at home and abroad will gather at Chengdu Medical City to attend alongside guests from various fields including government, industry, academia, research, finance, and media."First Future XDC New Drug Conference", jointly build a new ecosystem for the bioconjugation industry and touch the future pulse of the pharmaceutical industry.Host Organization |Chengdu Wenjiang District People's Government
Organizer |Chengdu Medical City Management Committee,Organization Department of the CPC Wenjiang District Committee of Chengdu City (District Talent Office),Wenjiang District Economic and Informatization Bureau of Chengdu City, Investment Promotion Bureau of Wenjiang District, Chengdu CityCo-organizer |China Pharmaceutical Enterprise Management AssociationEnterprise Support |Biokin, WuXi XDC, Tofflon, Zhongcheng Jiulian, Tot Biopharm, Yiman Biotechnology, WuXi AppTec, Quark Pharmaceuticals, R&G PHARMA STUDIES, NanoMicro Technology, Haoyuan Chemexpress, BGI, ATON, Bestchrom, Huixiang Information Technology, Haoyuan Chemexpress, Beijing NOVEL MEDICAL Equipment Ltd., Sinotau, Chengdu Xilingyuan Pharmaceutical, Hangzhou Healsun Biopharm, Shanghai Yinuosi Bio-Technology, Qide Medical Technology(Suzhou)Co., Ltd.DualityBio, Evergreen Therapeutics, Intellective, Dematic, Stemirna Therapeutics, SDIC Capital, Zhende Law Firm, Suntech Pharma, MediumBank Biotechnology, MITRO Biotech, Charles RiverConference Time |April 18-19, 2024Venue |Crowne Plaza Wenjiang ChengduMeeting Scale |1000+ people
Conference Chair: Yuquan WeiAcademician of the Chinese Academy of Sciences, Director of the State Key Laboratory of Biotherapy and Cancer Center at West China Hospital, Sichuan University
Opening Ceremony and Keynote MeetingBuild China's Biomedical Innovation Engine
2024/04/18
09:00-12:00
Opening Ceremony of the ConferenceBi Jingquan: Member of the 14th National Committee of the Chinese People's Political Consultative Conference (CPPCC), Executive Vice Chairman of the China Center for International Economic ExchangesLiu Jianxing: Deputy Director of the International Cooperation Center, National Development and Reform CommissionYuquan Wei: Academician of the Chinese Academy of Sciences, Director of the State Key Laboratory of Biotherapy and Cancer Center at West China Hospital, Sichuan UniversityZhao Xiangeng: Former Vice President and Academician of the Chinese Academy of EngineeringFrontiers in Immunology and Discovery of New Drug TargetsQi Hai: Dean of Tsinghua University School of MedicineCan ADC Change the Landscape of Cancer Treatment?Shen Lin: Director of the Department of Gastrointestinal Oncology, Peking University Cancer Hospital; Director of Phase I Clinical TrialsRoundtable Dialogue: Biotechnology, How to Move from Blossoming to Fruitful Results?Zhu Yi: Chairman of BiokinGe Junyou: General Manager of Kelun-BiotechLi Weimin: Former President of Huaxi HospitalWang Guowei: Global Partner of OrbiMedZhang Lianshan: Vice General Manager of Hengrui MedicineXie Xin: Executive Director and Senior Vice President of China Biologic ProductsYufen Zheng: Founder of Yueding Medical Fund
Session 1: ADC New Drug Development Model ForumEmbrace the Arrival of the Bioconjugate Drug Era
2024/04/18
13:30-18:00
13:30-13:50 ADC New Drug Development and Lung Cancer Treatment: Current Status and FutureZhou Caicun: President-Elect of the International Association for the Study of Lung Cancer13:50-14:10 ADC: Review and Outlook of BD TransactionsFu Tian: Co-founder and Chief Business Officer of OncoImmune14:10-14:30 The Transformation and Integrated Development Model of ADCLi Jincái: CEO of WuXi XDC14:30-14:50 Collaborative Innovation Model Spurs the Development of a New Generation of Bioconjugate DrugsQin Gang: Founder and Chairman of Qide Medical Technology(Suzhou)Co., Ltd.14:50-15:10 Developing Next-Generation ADCs Using Non-Natural Amino Acid Site-Specific Conjugation TechnologiesZhang Shaohui: Chief Scientific Officer and General Manager of Ambrx China15:10-15:30 Break
15:30-15:50 Challenges in XDC Registration and SubmissionChen Wei: Executive Director of Kant Concordia15:50-16:10 Global Patent Strategy for ADC's Overseas ExpansionTang Huadong: Partner of Zhede Law Firm16:10-16:30 Forecasting China's ADC R&D and Commercialization StrategiesLi Jing: Chairman of Yidu16:30-16:40 The Advanced Path of Intelligent Warehousing for Innovative DrugsHua Fang: Sales Manager of Dematic Pharmaceutical Industry16:40-17:20 Roundtable Dialogue 1:ADC DrugsDevelopment, Where to Go in the Future?Zhu Zhongyuan: Founder and CEO of Duality BiologicsShanshan Xu: Vice President of External Collaborations and Innovation at BioNTechBaiteng Zhao: Co-founder, Chairman and CEO of Proforma BiologicsTongtong Xue: Founder, Chairman and CEO of Yilian BiotechnologyLiu Dongzhou: Chief Scientific Officer of Huadong Medicine,General Manager of Global R&D Center for Innovative DrugsHua Jiang: Chairman and CEO of Boan Biotech17:20-18:00 Roundtable Discussion 2: ADC, How to Shape the Future of China's Pharmaceutical Industry?Chen Zhu: Chief Analyst of Healthcare Industry at CITIC SecuritiesWu Shengji: Chief Analyst of Morgan Stanley's Healthcare IndustryHe Ruyi:Rongchang BioCMO, Chief Scientist of SDIC Zhaoshang Pharmaceutical, Honorary Chairman of the New Drug Talent Club of TongxieyiXiao Zhi: Managing Director of SDIC InnovationTao Weikang: Vice President of Qilu Pharmaceutical Group and General Manager of the Global Innovation R&D SystemCao Yong: Vice President of China Business Development at BeiGene
Sub-forum 2: ADC New Applications and Novel Combination Therapies ForumExpand Larger Clinical Application SpaceCEO of Intellective Bio-Therapeutics
2024/04/19
09:00-12:15
09:00-09:25 Clinical Development Strategies for ADC Combination Therapies
Hei Yongjiang: CEO of Intellective09:25-09:45 ADC+IO: A New Era in Cancer TreatmentSui Ziye: Executive Director and General Manager of LePu Bio09:45-10:05 ADC+CAR-NK: Exploration and Prospect of Early Cancer Cure and Preventive TreatmentMiao Zhenwei: Founder and CEO of Immbright Biotech10:05-10:25 Some Challenges in ADC Drug DevelopmentXun Zhenming: Head of Global Biostatistics and Data Management at Daiichi Sankyo10:25-10:35 Break
10:35-10:55 From the Perspective of Clinical Successes and Failures: The Development of ADC TechnologyXiuqing Nie: CMO of New Code Biologics10:55-11:15 The Potential of ACT001 in Reducing Toxicity and Enhancing Sensitivity of ADC/RDC DrugsChen Yue: Founder and Chairman of Tianjin Suntech Pharmaceutical Technology Co., Ltd.11:15-11:35 Bi-XDC: A New Path to Drug DiscoveryXu Mo: Senior Vice President of Clinical Development at Tongyi Pharmaceuticals11:35-11:55 Research on the Preparation of More Stable ADCs Through Thiol CouplingMin 1: Head of ADC, Hangzhou Healsun Biopharm Co., Ltd.11:55-12:15 XDC Patent Layout StrategyWang Weibin: Managing Partner of Bixing Law Firm
Sub-Forum 3: New ADC Technology PlatformsBuild Core Key TechnologiesCo-organized by: Tot Biopharm, Suzhou Yiman Biotechnology Co., Ltd.
Executive Director and CEO of Tot Biopharm
2024/04/19
09:00-12:00
09:00-09:20 The Evolution and Development Cases of ADC Site-Specific Conjugation TechnologyLiu Jun: Executive Director and CEO of Tot Biopharm09:20-09:40 ADC Development Strategy Based on Glycan Site-Specific Conjugation TechnologyHuang Wei: Founder and Chairman of Tangling Biotech09:40-10:00 CPT Active Molecules and Their Chemical Site-Specific Conjugation Platform TechnologyZhao Yongxin: Founder and CEO of DuoXi Biotech
10:00-10:20 Design and Research of Peptide Conjugate Drugs Based on Peptide Discovery TechnologyLiu Huiqing: Senior Vice President of Zhongsheng Quan Peptide10:20-10:40 Break
10:40-11:00 Exploring the Next Generation of Conjugated Drugs NPDCZhang Fuyao: Chairman and General Manager of Biotech Bio
11:00-11:20 Application of Artificial Intelligence Cryogenic Robotics in the Quality and Safety Management of BiopharmaceuticalsZhang Jianxin:Suzhou Yiman Biotechnology Co., LtdChairman
11:20-11:40 Innovative ADC Linker Design and Payload SelectionHuang Jinkun: Founder and Chairman of Chengdu Xilingyuan Pharmaceutical Co., Ltd.11:40-12:00 Next-Generation High DAR, Multi-Payload ADC Conjugation PlatformYu Ninghui: CEO of Conway Biotech
Sub-forum 4: ADC New Targets and New Molecules ForumSeeking More Opportunities for Original InnovationChairman and CEO of Biokin
2024/04/19
13:00-15:40
13:00-13:20 Innovent's Claudin18.2-ADC R&D Experience SharingKaijie He: Vice President of Tumor Biology and ADC Drug Research, Innovent Guoqing Research Institute13:20-13:40 A Novel Claudin 18.2-Targeted ADC for Solid TumorsHu Yonghan: Co-founder, Director and Chief Technology Officer of Xinnuowei Pharmaceuticals13:40-14:00 The Competitive Landscape and Development Strategy of HER-2 ADCWei Ziping: Chairman and CEO of Biokin14:00-14:20 Nectin-4 ADC New Drug DevelopmentLiu Datao: Chairman and CEO of Mabwell
14:20-14:40 Review and Prospect of Bispecific Antibody-Drug Conjugates (ADC) DevelopmentBao Haifeng: Co-founder and CEO of BioRay Pharma1414:40-15:00 Non-clinical Evaluation Strategies and Case Analysis of ADC ProductsChang Yan: CEO of Shanghai Yinuosi Bio-Technology Co., Ltd.15:00-15:20 Use of bispecific strategies to reduce the toxicity of ADCsWang Chunhe: Founder and CSO of Dassault Pharmaceuticals15:20-15:40 Innovating ADC Conjugation by Reducing Side EffectsZhou Qing: Founder and CEO of Shijian Biotech
Sub-forum 5: ADC New Processes and Quality Control ForumPursuing Better Quality and Lower CostVice President of CMC, Large Molecule R&D Center, Kelun-Biotech
2024/04/19
13:00-16:00
13:00-13:20 Challenges and Strategies in CMC Development of ADC DrugsXiao Liang: Co-founder and COO of Yilian Biologics13:20-13:40 Key Considerations for ADC Production Quality ControlGong Wei: General Manager of CMC Operations at ATON13:40-14:00 Development of Bispecific ADC Process Based on PEG TechnologyLiu Shumin: Founder, Chairman and CEO of Kangyuan Jiuyuan14:00-14:20 Scale-up and Commercial Production of ADC ProcessesQuan Yong: Vice President of CMC, Large Molecule R&D Center, Kelun-Biotech14:20-14:40 Key CMC Considerations for ADC Dual IND Filing in China and the USDu New: CEO of Evergreen Therapeutics14:40-15:00 Strategies and Methods for Accelerating the ADC CMC Development CycleHu Jun: Executive Director of WuXi XDC15:00-15:20 Challenges and Coping Strategies in the Scale-Up Process of ADC ManufacturingZhuge Xin: Director of Process Development at Intellective15:20-15:40 Integrated Development Strategy, Challenges, and Case Analysis of ADC CMCWei Yaozhu: Head of ADC Process Development at Tot Biopharm15:40-16:00 Research Progress of ELP Conjugate DrugsGao Weiping: Department of Biomedical Engineering, Peking University
Future Nuclear Medicine Conference
Honorary Chairman of the US-China Nuclear Medicine and Molecular Imaging Society, Chief Advisor of Tongxieyi RadiopharmaceuticalsConference Chair: Li SijinEditor-in-Chief of Chinese Journal of Nuclear Medicine and Molecular Imaging, Chairman of the 11th Committee of Nuclear Medicine Branch of Chinese Medical Association, Former President of Shanxi Medical UniversityFull-process Development of Nuclear Medicine (Workshop)
2024/04/18
09:00-12:00
09:00-09:30 New Targets Lead the Future: Latest Developments in RadiopharmaceuticalsShen Di: Head of Sinotau's New Drug Innovation Promotion
09:30-10:00 Mastering the Core: A Comprehensive Analysis of Radiopharmaceuticals CMC
Xu Jianfeng: CMC Director of Sinotau
10:00-10:30 Analysis of Non-Clinical Evaluation Strategies for RDC New Drugs
Fu Peng: Shenzhen Development and Reform Commission Biomedical Industry Review Expert / Assistant President of Beijing Safu Pharmaceutical Research Institute
10:30-11:00 Tea Break
11:00-11:30 Strategy and Practice: The Path to Radiopharmaceutical Registration
Liu Shuang: Vice President of Sinotau New Drug Technology Center and Project Management
1112:30-12:00 Viewing the Radiopharmaceuticals Track from an Investment Perspective
Geng Xueli: Executive General Manager of SDIC Venture Capital
Sub-forum Six: Embracing the Future of the Nuclear Medicine IndustryHonorary Chairman of the U.S.-China Nuclear Medicine and Molecular Imaging Society, Chief Advisor of Tongxiyi Nuclear MedicineEditor-in-Chief of the Chinese Journal of Nuclear Medicine and Molecular Imaging, Chairperson of the 11th Committee of the Nuclear Medicine Branch of the Chinese Medical Association, Former President of Shanxi Medical University2024/04/18
13:30-17:50
1313:30-13:35 Introduction to the Nuclear Medicine Forum by the OrganizerZhang Yumin: Honorary Chairman of the US-China Nuclear Medicine and Molecular Imaging Society, Chief Advisor of Tongxieyi Radiopharmaceuticals13:35-13:40 Opening Remarks: Embracing the Revival of the Nuclear Medicine IndustryLi Sijin: Editor-in-Chief of Chinese Journal of Nuclear Medicine and Molecular Imaging, Chairman of the 11th Nuclear Medicine Branch of Chinese Medical Association, Former President of Shanxi Medical University
13:40-14:00 Clinical and Industry Dialogue—What Kind of Radiopharmaceuticals Does Nuclear Medicine Expect?
Clinical Guest:Li Sijin: Editor-in-Chief of Chinese Journal of Nuclear Medicine and Molecular Imaging, Chairman of the 11th Nuclear Medicine Branch of Chinese Medical Association, Former President of Shanxi Medical UniversityIndustry Guests:Zhang Yumin: Honorary Chairman of the Sino-American Nuclear Medicine and Molecular Imaging Society, Tongxiyi RadiopharmaceuticalsChiefGuAsk
14:00-14:20 Global Radiopharmaceuticals Industry Analysis and ForecastMao Hua: Partner and Managing Director of Sullivan Greater China
14:20-14:40 Advantages of Targeted Radiopharmaceuticals in the Treatment of Multiple Metastatic Tumors: Clinical Experience from Southwest Medical UniversityChen Yue: Professor/Director of the Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University
14:40-15:00 Novartis Radioligand Therapy and New Progress of Pluvicto in Prostate CancerLi Runqin: Head of Innovative Products, Medical Department, Novartis
15:00-15:20 Break
15:20-15:40 Innovative Layout of Traditional Nuclear Medicine Enterprises -- Dongcheng Pharmaceutical Nuclear Medicine Industry Layout and Progress
Luo Zhigang: General Manager of Dongcheng Pharmaceutical
15:40-16:00 Considerations in the Development Strategy of Radiopharmaceuticals
Li Hongyu: Chief Expert of China Isotope & Radiation Corporation / Radiopharmaceuticals Expert at Atomic High Tech
16:00-16:20 Unique Challenges in Nuclear Medicine Development
History Lin: Chief Medical Officer of Grand PharmaceuticalLiang Shuheng: Vice President of the Oncology Division, Grand Pharmaceutical
1616:20-16:40 From Introduction to Overseas Expansion: New Models and Case Studies in Innovative Nuclear Medicine R&D and Commercialization
Bai Ge: Vice President of Xiantong Pharmaceutical
1617:40-17:00 Construction of Specialized Services and Platform Capabilities for Nuclear Medicine Development
Zhong Wenjing: General Manager of Tongrui Biotech
17:00-17:50 Debate: Nuclear Medicine Biotech vs. Pharma -- A Battle of Wonders/Mutual Enhancement
Wang Zheng(Host)：CEO of Sinotau
Pharma
Wang Han: R&D Director of Chengdu Yunkhe Pharmaceutical Co., Ltd.
Guo Feihu: General Manager of Tianjin Hengrui Pharmaceutical Co., Ltd.
Yan Yuan: Investment Director of Yunnan Baiyao Group
Sui Yanying: Vice President of Atom High-Tech
Nuclear Medicine Biotech
Hao Hong: Chief Technology Officer of Sitikangchen
Qiao Tiecheng: CEO of AstraMed
Zeng Dexing: CSO of Hexin Pharmaceuticals
Bo Wave: CEO of Suzhou Borui Chuanghe
Sub-Forum Seven: Innovation and Frontier Technologies in Nuclear MedicineFounder and CEO of Intellective2024/04/19
09:00-12:00
09:00-09:20 High-Throughput Screening Technology and the Discovery and Optimization of Radiopharmaceuticals
Cheng Zhen: Director of the Molecular Imaging Center at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Deputy Director of the National Key Laboratory for Original New Drug Research09:20-09:40 Screening and Development of GPC3-Targeted RadiopharmaceuticalsQiao Tiecheng: CEO of Abozyme Pharmaceuticals
09:40-10:00 Mass Production of Cu-64 Radionuclide and Development of Cu-64 Labeled ProductsDu Fangyong: CSO of Tongrui Bio
10:00-10:20 Prospects for the Iteration and Upgrade of Targeted Radionuclide TherapyWang Yu: Co-founder/Chief Technology Officer of Crystal Core Biotech
10:20-10:30 Break
10:30-10:45 Clinical CROs Drive the Development of New Radiopharmaceuticals in China - Challenges and SolutionsZhang Lu: Senior Medical Director of Quark Pharmaceuticals
10:45-11:05 Pb-212 and Its Radiolabeled PharmaceuticalsBen Yong: Executive CEO of Nuclear Boat Pharmaceuticals
11:05-11:20 WuXi AppTec Supports Preclinical Research of RadiopharmaceuticalsShaowei Wang: Head of WuXi AppTec Molecular Imaging Center in Chengdu
11:20-12:00 Roundtable Discussion:From the Investor's Perspective: How to Drive Innovation in Nuclear MedicineLiu Chuanwen(Host): Partner of Xinjun Capital
Wu Yixia: CFO of Fluence PharmaceuticalsTian Qiang: Director of Medicinal Chemistry, Kelun-BiotechWang Chun: Chairman of Faber SkyZhu Yanfei: General Manager of Boyi Equity Investment FundSub-Forum 8: Nuclear Medicine Upstream and Downstream Industry Chain ForumCo-organized by: Tofflon Group
Head of the Drug Safety Evaluation Center, China Institute for Radiation Protection2024/04/19
13:00-15:50
13:00-13:20 Current Status of Medical Isotope Research and New Opportunities for Industrial Development
Zhang Jinsong: Deputy Director of the First Institute, China Nuclear Power Research and Design Institute13:20-13:40 Development of China-Made Medical Cyclotrons and IsotopesMario Marigli: General Manager of Jiuyi Yuan13:40-14:00 Localization of Medical Radioisotopes in China and Their ApplicationsCai Jiming: Co-founder/General Manager/Researcher of Chengdu Neurite14:00-14:20 Analysis of Practical Skills in the Production Process of RadiopharmaceuticalsHua Ning: Vice President of Xiantong Pharmaceutical / Production Director14:20-14:40 Considerations for CMC of RadiopharmaceuticalsWang Meng: Vice President of R&D and Chief Operating Officer of Nuoyu Pharmaceuticals14:40-15:00 Clinical Trial Design for RadiopharmaceuticalsDong Qinsheng: Medical Director of Stem Medical Center15:00-15:20 System Solutions for Radiopharmaceutical ProductionYu Kui: General Manager of Tofflon Nuclear Medicine Business15:20-15:50 Roundtable Dialogue: Collaborative Innovation and Intensive Development in Nuclear MedicineYang Yuchuan(Host)Deputy Director of the Institute of Nuclear Physics and Chemistry, China Academy of Engineering PhysicsLi Shisheng: Deputy Chief Engineer of Qinshan Nuclear PowerZhang Li: Head of the Nuclear Medicine Industry at Chengdu Medical CityLiu Mai: Chairman of Beijing NOVEL MEDICAL Equipment Ltd.Tian Haibin: Chairman/CEO of Hanhe MedicalZhuo Weibin: Co-founder of Astatine Alpha NuclideFreehand Evening Party: The Sky of BioconjugationSupport: WuXi XDC, Biokin✨Time: April 18, 2024, 18:30-20:30
▪ Release of New ADC and Nuclear Medicine Forces(Sullivan)
▪ Pharmaceutical Company XDC Project Cooperation Requirements Release
▪ XDC Ecosystem Construction
Contact:Xu Zhen 19942087621
By invitation only for report guests and presidents of member institutions of Tongxiyi. Non-invited guests must pay a registration fee of 2000 RMB per person.
Supporting Institution Solicitation
*This event offers various business cooperation opportunities, including on-site booths.
Warm Tips:
1. This event is entirely based onOnline RegistrationThe way.
2. The registration fee includes a customized badge, conference manual, lunch on April 18th-19th, tea breaks, etc. Early bird tickets are non-refundable but transferable.
3. Become a member of Tongxiyi to enjoy multiple benefits! For membership application, please consult Tongxiyi's business personnel.
1. Crowne Plaza Wenjiang Chengdu (Conference Hotel)
Reference Price: 560 RMB/room(Including breakfast)
Room Reservation Inquiry: 028-82628888
2. Holiday Inn Express Wenjiang Hot Spring, Chengdu (next to the conference hotel)
Reference Price: 350 RMB/room(Including breakfast)
Room Reservation Inquiry: 028-82628888
Tongxiyi:010-83634390/83634290
Registration Consultation:Ding Jieyi: 19910274182
Weng Qi: 17751479618
Li Zhen: 13522802756
Lin Ruiming: 17365430165
Click here to read the original text and sign up immediately.
"WeChat Official Account of Chinese Nuclear Medicine Physicians"
Host Organization
Editor: Li Chunlin
Number of followers: 40,000+ people
Issue No. 2916
March 7, 2024
Focus on Chinese Nuclear Medicine PhysiciansPractice medicine legally, uphold rights legallyWelcome to forward and welcome to reprint
Welcome to follow
《Official Website of the Nuclear Medicine Physicians Branch of the Chinese Medical Doctor Association》
http://www.caonmp.com/
Statement:
The copyright of this article belongs to the original author, and does not represent the position of this WeChat Official Account.
If involving copyright matters, please contact for removal.
